Expert Insights on New Systemic Therapies for Advanced Prostate Cancer

Join us for an engaging live meeting focused on optimizing therapy for patients with advanced prostate cancer. Gain expert insight from CCO’s renowned faculty members Daniel Petrylak, MD (program chair), Daniel W. Lin, MD, and David F. Penson, MD, who will discuss systemic therapies for nonmetastatic CRPC, combinations of ADT with other therapies for metastatic prostate cancer, the risk of cardiotoxicity and bone loss, and current clinical trials throughout the prostate cancer disease continuum.

Agenda

7:30 AM – 8:00 AM  Registration and Breakfast

8:00 AM – 8:10 AM  Program Overview
Daniel P. Petrylak, MD, PhD (Program Chair)

8:10 AM – 8:35 AM  Biomarkers for Risk Stratification and Advances in Nonmetastatic Castration Resistant Prostate Cancer
David F. Penson, MD 

8:35 AM – 9:00 AM  What are the Current Recommendations for Metastatic Hormone-Sensitive Prostate Cancer?
Daniel W. Lin, MD

9:00 AM – 9:20 AM  Emerging Use of Biomarkers for Optimal Management of Metastatic CRPC
Daniel P. Petrylak, MD, PhD

9:20 AM – 9:30 AM  Conclusions and Audience Q&A Session

Events

Date / Time
Event Details

Faculty

Program Chair
Daniel Petrylak, MD, PhD

Faculty
Daniel W. Lin, MD

Professor and Chief of Urologic Oncology
Department of Urology
University of Washington
Seattle, Washington

Faculty
David F. Penson, MD

Professor and Chair
Department of Urology
Vanderbilt University School of Medicine
Nashville, Tennessee

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating recent findings into the treatment of patients with prostate cancer.

Target Audience
This program is intended for physicians, urologists, and other healthcare providers who care for patients with prostate cancer.

Learning Objectives 

  • Plan optimal, individualized therapeutic strategies for patients with advanced prostate cancer through exposure to expert insights and recommendations, real-world experience, and evidence- and consensus-based guidelines
  • Evaluate new therapeutic options for nonmetastatic castration-resistant prostate cancer
  • Compare combinations of ADT with various agents vs ADT alone for M0 or metastatic hormone-sensitive prostate cancer
  • Assess and manage the risk for cardiotoxicity or bone loss prior to and/or during prostate cancer treatment
  • Refer appropriate patients with prostate cancer to ongoing clinical trials assessing novel therapies alone and in combination throughout the disease continuum to aid in trial enrollment

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Pharmacists

NCCN designates this knowledge-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-9999-19-027-L01-P

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

Physician Assistants

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.